Literature DB >> 2446546

Antibody heterogeneity and specificity in myasthenia gravis.

A Vincent1, P J Whiting, M Schluep, F Heidenreich, B Lang, A Roberts, N Willcox, J Newsom-Davis.   

Abstract

Anti-AChR is heterogeneous within individuals and between individuals. Anti-AChR idiotypes are not shared to any large extent. Ten monoclonal antibodies raised against human AChR: (a) bind to five partially overlapping regions; (b) are not idiotypically identical even within a region; (c) do not all bind to the main immunogenic region; (d) four distinguish between normal and denervated human AChR; (e) can be used to define the antigenic determinants in MG. Antigenic specificities vary in different clinical groups. Antigenic specificities can change during the course of the disease, but some remain relatively constant. Thymus cultures make antibodies with the same specificity as those present in the serum of the individual. All monoclonal antibodies bind to myoid cells of normal and MG thymus. We find no convincing evidence of naturally occurring antiidiotype antibodies in MG sera.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2446546     DOI: 10.1111/j.1749-6632.1987.tb51286.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  15 in total

1.  Prevention of passively transferred experimental autoimmune myasthenia gravis by a phage library-derived cyclic peptide.

Authors:  N Venkatesh; S H Im; M Balass; S Fuchs; E Katchalski-Katzir
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

2.  Antibodies to acetylcholine receptors in patients with different clinical forms of myasthenia and Lambert-Eaton myasthenic syndrome.

Authors:  D V Sidnev; M Yu Karganov; N I Shcherbakova; I B Alchinova; A G Sanadze
Journal:  Neurosci Behav Physiol       Date:  2007-02

3.  Decrease in the carbamylcholine-induced chemotaxis of monocytes in myasthenia gravis.

Authors:  S Sipka; P Diószeghy; F Mechler; K Lukács; J Szelényi; G Szegedi
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1991       Impact factor: 5.270

Review 4.  Myasthenia gravis: an autoimmune response against the acetylcholine receptor.

Authors:  Y M Graus; M H De Baets
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

Review 5.  Myasthenia gravis as a prototype autoimmune receptor disease.

Authors:  A C Hoedemaekers; P J van Breda Vriesman; M H De Baets
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

6.  Synthesis of anti-acetylcholine receptor antibodies by CD5- B cells from peripheral blood of myasthenia gravis patients.

Authors:  F Heidenreich; T Jovin
Journal:  J Neurol       Date:  1996-01       Impact factor: 4.849

7.  Epitopes expressed in myasthenia gravis (MG) thymomas are not recognized by patients' T cells or autoantibodies.

Authors:  N Nagvekar; L W Jacobson; N Willcox; A Vincent
Journal:  Clin Exp Immunol       Date:  1998-04       Impact factor: 4.330

8.  A pathogenetic role for the thymoma in myasthenia gravis. Autosensitization of IL-4- producing T cell clones recognizing extracellular acetylcholine receptor epitopes presented by minority class II isotypes.

Authors:  N Nagvekar; A M Moody; P Moss; I Roxanis; J Curnow; D Beeson; N Pantic; J Newsom-Davis; A Vincent; N Willcox
Journal:  J Clin Invest       Date:  1998-05-15       Impact factor: 14.808

9.  T helper cell recognition of muscle acetylcholine receptor in myasthenia gravis. Epitopes on the gamma and delta subunits.

Authors:  A A Manfredi; M P Protti; M W Dalton; J F Howard; B M Conti-Tronconi
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

10.  Myasthenia gravis. CD4+ T epitopes on the embryonic gamma subunit of human muscle acetylcholine receptor.

Authors:  M P Protti; A A Manfredi; X D Wu; L Moiola; M W Dalton; J F Howard; B M Conti-Tronconi
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.